Entropy Neurodynamics Limited · ASX:ENP
Entropy Neurodynamics — Investor Presentation (July 2026)
14 slides from Entropy Neurodynamics's investor presentation, Jul 9, 2026
Slide 1: Landmark clinical results in treatment-resistant Binge Eating Disorder
ENTROPY er NEURODYNAMICS" ) 2 S fo) 0) ) =} Landmark clinical results in treatment-resistant Binge Eating Disorder July 2026 This presentation has been authorised for release by the Board of Entropy Neurodynamics Limited
Slide 2: Disclaimers
Disclaimers tenes aed on unter of xeon cient a pe, change athe ate heer the ater pc refrnced inthis Prsentan af exes unified by hs autona cues mht ey ia cer jt oh es are 0 verified the undertying reports reied upon or! th sources, or ascertained the underying as for that information or thote opinion
Slide 3: Company Overview
Company Overview Ne > Entropy Neurodynamics is a clinical-stage biotechnology company developing next- generation psychedelic medicine for neuropsychiatric disorders > Entropy’s proprietary IV-delivered psilocin therapy, TRP-8803, is designed to provide a rapid, precise, reversible and predictable t
Slide 4: Corporate Overview
p> 4) Corporate Overview Corporate Snapshot > ASX code ENP Top 20 Holders = Shares on issue: 1.632Bn je) Market capitalisation Cash at bank: AU$6.5m (31 March 2026) Shareholders (at 03 July 2026) Debt Nil Dr. William James Garner (Co-founder) 13.6% Dr. Daniel Tillett (VED) 41% Board of Directors Mr.
Slide 5: Previous signal studies have laid a strong scientific foundation
Previous signal studies have laid a strong scientific foundation TAM AUS42.6Bn TAM AUS14.7Bn TAM AU$88.2Bn Fibromyalgia (FM) Binge Eating Disorder (BED) _ Irritable Bowel Syndrome (IBS) se only A * Multi-Domain Improvement * Binge Episodes 10.8 — 0 * Clinically Meaningful, by Week 6 Durable Reductio
Slide 6: TRP-8803 has been specifically designed to remove the barriers to therapy
TRP-8803 has been specifically designed to remove the barriers to therapy TRP-8803 : A Precision approach in Neuropsychiatry 2 > IV-infused Psilocin Oral Psilocybin * ® Short treatment duration of 1-2 hours oY x] “8-10 hours f) =| x] 1-2 hours x} highly variable x) Od e Quick onset of psychedelic st
Slide 7: Phase 2 TRP-8803 trial in treatment-resistant Binge-Eating Disorder (BED)
Phase 2 TRP-8803 trial in treatment-resistant Binge-Eating Disorder (BED) > Overview: Phase 2, open-label clinical trial conducted in collaboration with Swinburne University > Objective: Evaluate the safety, tolerability and preliminary efficacy of TRP-8803 > Therapy: Proprietary precision-controlle
Slide 8: Landmark Clinical Trial Results with TRP-8803
Landmark Clinical Trial Results with TRP-8803 World-first results highlight TRP-8803’s potential as a treatment route = TRP-8803 delivered 50% remission in treatment-resistant Binge Eating fo) Disorder and clinical improvement in 100% of patients (<b) 72) Clinical safety and efficacy results represe
Slide 9: Topline results from treatment-resistant binge-eating-disorder
Topline results from treatment-resistant binge-eating-disorder 100% of patients achieved clinically meaningful BED symptom improvements 57% (8-point) reduction in Depression (PHQ-9) 50% of treatment-resistant BED patients achieved clinical remission (zero BED episodes) ~~ Li! 74% reduction in binge
Slide 10: Strategic Significance
Strategic Significance Cohort 1 represents a pivotal clinical milestone for Entropy. As the world’s first efficacy data generated from precision-controlled, IV-psilocin, the study demonstrates that TRP-8803 delivers rapid, reproducible and clinically meaningful therapeutic benefit in patients with r
Slide 11: Global Pharma chasing differentiated Phase assets on minimal patient data
Global Pharma chasing differentiated Phase 2 assets on minimal patient data AbbVie to Acquire Gilgamesh Pharmaceuticals’ Bretisilocin = Cc [e) AUGUST 25, 2025: AU$1.75Bn transaction for a pharmaceutical small molecule, bretisilocin (at Phase 2a) (<b) is a very potent signal from the company consider
Slide 12: Aggressive Absorption of Global Intellectual Property Portfolio rights
Aggressive Absorption of Global Intellectual Property Portfolio rights Patent applications and trade secrets based on novel methods for manufacturing, formulation, dosing and > treatment of specific disease indications have been filed for all major global pharmaceutical markets Te fo) = Provisional
Slide 13: Historical Milestones & Pending Catalysts
Historical Milestones & Pending Catalysts Milestone Timing Status ‘Completion of TRP-8803 Phase 1 study in healthy human volunteers (14) H3CY24 v fo) ITRP-8802 Positive Fibromyalgia and BED Phase 2a interim data (University of Michigan & Hicy24 ly ) Florida) TRP-8803 BED Phase 2a BED trial commencem
Slide 14: Contact
ENTROPY NEURODYNAMICS CONTACT Jason Carroll Chief Executive Officer jcarroll@tryptherapeutics.com Website: www.entropyneurodynamics.com Henry Jordan Six Degrees Investor Relations henry.jordan@sdir.com.au Socials: X (Twitter) @tryptherapeutic
Entropy Neurodynamics — Investor Presentation (July 2026) on 6ix